HTG Molecular Diagnostics (HTGMQ) 10-Q 14 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 04, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	1,169,987
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		7,065,254

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 5,523,824	$ 3,293,983
Short-term investments available-for-sale, at fair value	11,097,140	28,201,507
Accounts receivable	591,861	716,246
Inventory, net of allowance of $667,553 at September 30, 2016 and $284,319 at December 31, 2015	1,867,685	2,201,301
Prepaid insurance	215,236	234,777
Prepaid expenses and other	226,070	210,440
Total current assets	19,521,816	34,858,254
Long-term investments available-for-sale, at fair value		2,603,901
Property and equipment, net	3,666,947	1,932,213
Total assets	23,188,763	39,394,368
Current liabilities:
Accounts payable	1,117,830	724,805
Accrued liabilities	1,292,285	1,915,268
Deferred revenue	283,663	47,476
NuvoGen obligation	582,614	543,750
Term loan	6,254,688	3,059,068
Other current liabilities	270,041	29,243
Total current liabilities	9,801,121	6,319,610
Term loan payable - non-current, net of discount and debt issuance costs	6,902,379	7,737,586
NuvoGen obligation - non-current, net of discount	8,169,861	8,415,122
Other	530,159	28,652
Total liabilities	25,403,520	22,500,970
Commitments and Contingencies
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2016 and December 31, 2015, 7,060,269 and 7,058,873 shares issued and outstanding, respectively, at September 30, 2016, 6,845,638 and 6,844,242 shares issued and outstanding, respectively, at December 31, 2015	7,059	6,844
Additional paid-in-capital	107,786,467	106,569,405
Treasury stock – 1,396 shares, at cost	(75,000)	(75,000)
Accumulated other comprehensive loss	(320)	(41,357)
Accumulated deficit	(109,932,963)	(89,566,494)
Total stockholders’ equity (deficit)	(2,214,757)	16,893,398
Total liabilities and stockholders' equity (deficit)	$ 23,188,763	$ 39,394,368

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Inventory net allowance	$ 667,553	$ 284,319
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	7,060,269	6,845,638
Common stock, shares outstanding	7,058,873	6,844,242
Treasury stock, shares	1,396	1,396

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Product	$ 506,065	$ 973,956	$ 1,683,382	$ 2,349,740
Service	407,836	37,000	1,991,567	150,292
Other				325,789
Total revenue	913,901	1,010,956	3,674,949	2,825,821
Cost of revenue	1,125,009	809,015	2,901,455	2,538,590
Gross margin	(211,108)	201,941	773,494	287,231
Operating expenses:
Selling, general and administrative	3,937,600	3,717,402	13,343,945	10,883,161
Research and development	1,910,116	1,309,573	6,515,808	2,951,009
Total operating expenses	5,847,716	5,026,975	19,859,753	13,834,170
Operating loss	(6,058,824)	(4,825,034)	(19,086,259)	(13,546,939)
Other income (expense):
Loss from change in stock warrant valuation	0	0	0	(239,683)
Interest expense	(490,825)	(378,656)	(1,422,171)	(1,334,103)
Interest income	26,196	37,788	92,767	48,930
Loss on settlement of convertible debt				(705,217)
Other	35,011	8,239	53,453	78,873
Total other income (expense)	(429,618)	(332,629)	(1,275,951)	(2,151,200)
Net loss before income taxes	(6,488,442)	(5,157,663)	(20,362,210)	(15,698,139)
Income taxes			4,259
Net loss	(6,488,442)	(5,157,663)	(20,366,469)	(15,698,139)
Accretion of stock issuance costs				(35,046)
Accretion of Series E warrant discount				(127,616)
Accretion of Series D and E redeemable convertible preferred stock dividends				(1,165,932)
Net loss attributable to common stockholders	$ (6,488,442)	$ (5,157,663)	$ (20,366,469)	$ (17,026,733)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.92)	$ (0.76)	$ (2.92)	$ (4.56)
Shares used in computing net loss per share attributable to common stockholders, basic and diluted	7,053,010	6,829,687	6,985,924	3,735,852

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (6,488,442)	$ (5,157,663)	$ (20,366,469)	$ (15,698,139)
Other comprehensive income (loss), net of tax effect:
Unrealized gain (loss) on short and long-term investments	(2,836)	12,993	41,037	4,754
Comprehensive loss	(6,491,278)	(5,144,670)	(20,325,432)	(15,693,385)
Less: Accretion of stock issuance costs				(35,046)
Less: Accretion of Series E warrant discount				(127,616)
Less: Accretion of Series D and E redeemable convertible preferred stock dividends				(1,165,932)
Comprehensive loss attributable to common stockholders	$ (6,491,278)	$ (5,144,670)	$ (20,325,432)	$ (17,021,979)

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Deficit) - 9 months ended Sep. 30, 2016 - USD ($)	Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2015	$ 16,893,398	$ 6,844	$ 106,569,405	$ (75,000)	$ (41,357)	$ (89,566,494)
Balance, shares at Dec. 31, 2015		6,844,242
Stock issued for payment of 2015 annual bonus	364,910	$ 133	364,777
Stock issued for payment of 2015 annual bonus, shares		133,179
Exercise of stock options	10,132	$ 5	10,127
Exercise of stock options, shares		4,712
Stock-based compensation expense	552,054	$ 37	552,017
Stock-based compensation expense, shares		36,762
Employee stock purchase plan purchases	167,721	$ 40	167,681
Employee stock purchase plan purchases, shares		39,978
Growth Term Loan B warrant discount	122,460		122,460
Net loss	(20,366,469)					(20,366,469)
Other comprehensive income	41,037				41,037
Balance at Sep. 30, 2016	$ (2,214,757)	$ 7,059	$ 107,786,467	$ (75,000)	$ (320)	$ (109,932,963)
Balance, shares at Sep. 30, 2016		7,058,873

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities
Net loss	$ (20,366,469)	$ (15,698,139)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,086,752	473,799
Accretion of discount on NuvoGen obligation	156,103	229,232
Bad debt expense, net of recoveries		44,854
Provision for excess inventory	437,893	273,752
Amortization of Growth Term Loan discount and issuance costs	415,355	274,486
Loss on settlement of convertible notes		705,217
Amortization of discount on convertible notes		90,222
Stock-based compensation expense	552,054	223,787
Change in redeemable convertible preferred stock warrant liability	0	239,683
Accretion of incentive from landlord	(94,667)
Accrued interest on available-for-sale securities investments	130,576
Loss on disposal of assets		67,780
Changes in operating assets and liabilities:
Accounts receivable	124,385	59,444
Inventory	(104,277)	(854,120)
Prepaid expenses and other	3,911	(505,918)
Accounts payable	367,529	(254,423)
Accrued liabilities	(258,073)	(47,367)
Deferred revenue	236,187	(8,532)
Net cash used in operating activities	(17,312,741)	(14,686,243)
Investing activities
Purchase of property and equipment	(1,859,155)	(950,278)
Sales, redemptions and maturities of available-for-sale securities	23,000,000
Purchase of available-for-sale securities	(3,381,271)	(36,473,957)
Net cash provided by (used in) investing activities	17,759,574	(37,424,235)
Financing activities
Proceeds from initial public offering		47,654,190
Deferred offering costs		(1,002,930)
Proceeds from Growth Term Loan	5,000,000
Payments on Growth Term Loan	(2,932,482)
Proceeds from convertible notes		4,500,000
Deferred convertible note financing costs		(75,523)
Payments on capital leases	(99,863)	(21,933)
Proceeds from exercise of stock options	10,132	34,048
Proceeds from exercise of Series E warrants		8,948
Proceeds from issuance of convertible note warrants		1,354
Proceeds from shares purchased under the stock purchase plan	167,721
Payments on NuvoGen obligation	(362,500)
Settlement of fractional common shares		(2,925)
Net cash provided by financing activities	1,783,008	51,095,229
Increase (decrease) in cash and cash equivalents	2,229,841	(1,015,249)
Cash and cash equivalents at beginning of period	3,293,983	3,613,392
Cash and cash equivalents at end of period	5,523,824	2,598,143
Noncash investing and financing activities
Accretion of preferred stock issuance costs		35,046
Accretion of dividends		1,165,932
Deferred offering costs reclassified to distributions in excess of capital		2,297,079
Allocation of Series E warrant convertible notes debt discount		741,828
Conversion of convertible notes and related accrued interest to common stock		4,544,384
Reclassification of convertible preferred stock liability warrants to equity warrants		(1,616,140)
Fixed asset purchases payable and accrued at period end	25,496	272,847
Stock issued for settlement of accrued bonus	(364,910)
Purchase of property and equipment under capital lease	226,835
Incentive from landlord	710,000
Supplemental cash flow information
Cash paid for interest	$ 850,713	701,250
Common Stock
Noncash investing and financing activities
Conversion of convertible preferred stock to common stock		(57,356,049)
Series D And E Redeemable Convertible Preferred Stock
Noncash investing and financing activities
Accretion of dividends		1,165,932
Series D and Series E Warrants
Noncash investing and financing activities
Exercise of warrants		(95,914)
Series E Warrants
Noncash investing and financing activities
Accretion of warrant discount		$ 127,616

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business HTG Molecular Diagnostics, Inc. (the “Company”) is a commercial stage company that develops and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its proprietary nuclease protection chemistry on a wide variety of biological samples. The Company derives revenue from the sale of instruments, consumables and related services. The Company operates in one segment and its customers are primarily located in the United States. For the three and nine months ended September 30, 2016, approximately 15% and 11%, respectively, of the Company’s revenue was generated from sales to customers located outside of the United States, compared with 24% and 11%, respectively, for the three and nine months ended September 30, 2015.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Note 2. Basis of Presentation Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect the accounts of the Company as of September 30, 2016. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The unaudited condensed balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 24, 2016. Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Going Concern The Company implemented the criteria of Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The Company will need to raise additional capital to fund its operations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. If sufficient additional capital is not available as and when needed, the Company may have to delay, scale back or discontinue one or more product development programs, curtail its commercialization activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize independently, cease operations altogether, pursue an acquisition of the Company at a price that may result in up to a total loss on investment for its stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all assets. Change in Accounting Principle In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-03, Interest – Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long-lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, available‑for‑sale debt securities and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three and nine months ended September 30, 2016 and 2015 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Instruments $ 5,846 $ 338,231 $ 88,146 $ 597,426 Consumables 500,219 635,725 1,595,236 1,752,314 Total product sales $ 506,065 $ 973,956 $ 1,683,382 $ 2,349,740 The Company’s top three customers accounted for 27%, 24% and 9% of the Company’s revenue for the three months ended September 30, 2016, compared with 26%, 16% and 12% for the three months ended September 30, 2015. The top three customers accounted for 38%, 14% and 7% of the Company’s revenue for the nine months ended September 30, 2016, compared with 29%, 10% and 6% of the Company’s revenue for the nine months ended September 30, 2015. The top two customers accounted for approximately 59% and 11% of the Company’s net accounts receivable as of September 30, 2016, compared with approximately 32% and 25% as of December 31, 2015. The Company currently relies on a single supplier to supply a subcomponent used in the HTG Edge and HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of HTG Edge and HTG EdgeSeq systems, which in turn would materially affect the Company’s ability to generate revenue. Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers The revised revenue standard is effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its financial statements and has not yet determined the method by which it will adopt the standard. In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-09, Share-Based Payment: Simplifying the Accounting for Share-Based Payments In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients . will have the same effective date and transition requirements as ASU 2014‑09. The Company is currently evaluating the effect the adoption of ASU 2016-12 will have on its financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments

Inventory

Inventory	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory HTG Edge or HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Equipment that is under evaluation for purchase remains in inventory as the Company retains title to the equipment throughout the evaluation period. The period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may be extended beyond 180 days. If the customer has not completed the purchase of the instrument by the end of the initial evaluation period, the Company will determine whether to extend the evaluation period or have the equipment returned to the Company. If the customer has not purchased the equipment or entered into a reagent agreement with the Company within one year, the equipment is returned to the Company or the customer is allowed to continue use of the equipment in which case the cost of the equipment is written off to selling, general and administrative expense. Inventory, net of allowance, consisted of the following as of the date indicated: September 30, December 31, 2016 2015 Raw materials $ 1,584,273 $ 1,274,840 Work in process 1,991 — Finished goods 948,974 1,210,780 Total gross inventory 2,535,238 2,485,620 Less inventory allowance (667,553 ) (284,319 ) $ 1,867,685 $ 2,201,301 For the three and nine months ended September 30, 2016, the Company recorded adjustments to provision for excess inventory $288,130 and $437,893, respectively, resulting in a net adjustment to inventory allowance of $291,692 and $383,234, respectively. For the three and nine months ended September 30, 2015, the Company recorded adjustments to provision for excess inventory of $76,799 and $330,088, respectively, resulting in a net adjustment to the inventory allowance of $62,872 and $273,752, respectively. Adjustments in these periods to the allowance for estimated shrinkage and obsolescence and excess inventory were recognized within cost of revenue in the condensed statements of operations. During the nine months ended September 30, 2016 and 2015, the Company wrote off $54,659 and $56,336, respectively, of obsolete inventory against the inventory allowance.

Fair Value Instruments

Fair Value Instruments	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Instruments	Note 4. Fair Value Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The Company’s portfolio of available-for-sale securities comprises U.S. Treasuries, U.S. government sponsored agency obligations and high credit quality corporate debt securities. Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy, based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2016 and December 31, 2015, respectively in the fair value hierarchy: Balance at September 30, 2016 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 4,897,198 $ — $ — $ 4,897,198 Investments available-for-sale at fair value U.S. government obligations $ 1,302,991 $ — $ — $ 1,302,991 U.S. government agency obligations $ — $ 3,582,980 $ — $ 3,582,980 Corporate debt securities $ — $ 6,211,169 $ — $ 6,211,169 Balance at December 31, 2015 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 3,290,490 $ — $ — $ 3,290,490 Investments available-for-sale at fair value U.S. government obligations $ 3,298,014 $ — $ — $ 3,298,014 U.S. government agency obligations $ — $ 14,589,378 $ — $ 14,589,378 Corporate debt securities $ — $ 12,918,016 $ — $ 12,918,016 There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and nine months ended September 30, 2016 or 2015. Level 1 instruments include investments in money market funds and U.S. Treasuries. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include U.S. Government agency obligations and corporate debt securities. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g. indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for the periods ended September 30, 2016 or December 31, 2015.

Available for Sale Securities

Available for Sale Securities	9 Months Ended
	Sep. 30, 2016
Investments Debt And Equity Securities [Abstract]
Available for Sale Securities	Note 5. Available for Sale Securities The following is a summary of the Company’s available-for-sale securities at September 30, 2016 and December 31, 2015: September 30, 2016 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities and obligations of U.S. government agencies $ 4,884,459 $ 1,511 $ — $ 4,885,970 Corporate debt securities 6,213,001 $ — (1,831 ) 6,211,170 Total available-for-sale securities $ 11,097,460 $ 1,511 $ (1,831 ) $ 11,097,140 December 31, 2015 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities and obligations of U.S. government agencies $ 17,914,136 $ — $ (26,744 ) $ 17,887,392 Corporate debt securities 12,932,629 397 (15,010 ) 12,918,016 Total available-for-sale securities $ 30,846,765 $ 397 $ (41,754 ) $ 30,805,408 The net adjustment to unrealized holding gains (losses) on available-for-sale securities in other comprehensive income totaled $(2,836) and $41,037 for the three and nine months ended September 30, 2016, respectively, and $12,993 and $4,754 for the three and nine months ended September 30, 2015, respectively. Contractual maturities of debt investment securities at September 30, 2016 are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total U.S. Treasury securities and obligations of U.S. government agencies $ 4,885,970 $ — $ 4,885,970 Corporate debt securities 6,211,170 — 6,211,170 Total available-for-sale securities $ 11,097,140 $ — $ 11,097,140 The following table shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of September 30, 2016: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses U.S. Treasury securities and obligations of U.S. government agencies $ — $ — $ — $ — $ — $ — Corporate debt securities 2,817,800 (1,831 ) — — 2,817,800 (1,831 ) Total available-for-sale securities with unrealized losses $ 2,817,800 $ (1,831 ) $ — $ — $ 2,817,800 $ (1,831 ) For debt securities, management determines whether it intends to sell or if it is more likely than not that it will be required to sell impaired securities. This determination considers current and forecasted liquidity requirements, regulatory and capital requirements and securities portfolio management. If so, any impairment would be recognized through earnings. For all impaired debt securities for which there was no intent or expected requirement to sell, the evaluation considers all available evidence to assess whether it is likely the amortized cost value will be recovered, considering, among other factors, the nature of the securities, credit rating or financial condition of the issuer, the extent and duration of the unrealized loss, expected cash flows of underlying collateral and market conditions. The Company did not have any other-than-temporary impairment in its debt securities for the three and nine months ended September 30, 2016.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net, consists of the following: September 30, December 31, 2016 2015 Office equipment $ 499,362 $ 257,296 Leasehold improvements 1,847,378 224,061 Laboratory and manufacturing equipment 3,445,446 2,442,191 Field equipment 131,096 180,355 Software 140,248 140,248 Construction in progress 145,063 175,501 6,208,593 3,419,652 Less: accumulated depreciation and amortization (2,541,646 ) (1,487,439 ) $ 3,666,947 $ 1,932,213 Depreciation and leasehold improvement amortization expense was $357,924 and $1,086,752 for the three and nine months ended September 30, 2016, respectively, and $174,390 and $473,799 for the three and nine months ended September 30, 2015, respectively. At September 30, 2016, the total cost and accumulated amortization of assets under lease commitments were $373,048 and $188,179, respectively, while cost and accumulated depreciation at December 31, 2015 were $146,213 and $88,220, respectively. Leased asset amortization has been included in depreciation and amortization expense within the condensed statements of operations for the three and nine months ended September 30, 2016 and 2015. During the first quarter of 2016, the Company capitalized landlord funded lease incentives as leasehold improvements to be amortized over the shorter of the useful life or the remaining life of the real estate lease (see Note 14).

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following: September 30, December 31, 2016 2015 Employee compensation and benefits $ 756,501 $ 1,240,314 Employee compensation for future absences 160,183 154,107 Interest 93,413 77,917 Professional fees 63,480 140,385 Other 218,708 302,545 $ 1,292,285 $ 1,915,268

Debt Obligations

Debt Obligations	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations Growth Term Loan In August 2014, the Company entered into a Loan and Security Agreement (the “Growth Term Loan”) with a syndicate of two lending institutions, Oxford Finance LLC and Silicon Valley Bank, which was amended in August 2015 and June 2016. The first tranche of the Growth Term Loan (“Growth Term Loan A”) of $11.0 million was funded in August 2014. The second tranche of $5.0 million (“Growth Term Loan B”) was funded in March 2016. The August 2015 amendment extended the monthly interest-only payment period until April 1, 2016. Following the interest-only payment period, the Company became obligated to make equal monthly payments of principal and interest amortized over the remaining term of the loan for all funds drawn under Growth Term Loan A and B. Growth Term Loan A and B bear interest at the fixed rates of 8.5% and 8.75%, respectively and mature in September 2018. Should a prepayment be made, the Company will be obligated to pay a prepayment fee equal to (i) 3% of the principal amount prepaid if the growth term loan is prepaid on or before the first anniversary of the August 2015 amendment, (ii) 2% of the principal amount repaid if the growth term loan is prepaid after the first anniversary but on or prior to the second anniversary of the August 2015 amendment and (iii) 1% of the principal amount repaid if the growth term loan is repaid after the second anniversary of the August 2015 amendment and prior to maturity. The amendment also increased the final payment percentage to 4.75%. The June 2016 amendment modified the definitions of permitted indebtedness and permitted liens to provide for an increased maximum amount of permitted indebtedness, authorize a new category of permitted indebtedness and authorize a new category of permitted liens. The Growth Term Loan requires the Company to maintain compliance with specific reporting covenants and does not require financial covenants. The Growth Term Loan is secured by a lien covering substantially all of the Company’s assets, excluding patents, trademarks and other intellectual property rights (except for rights to payment related to the sale, licensing or disposition of such intellectual property rights) and certain other specified property. The Company received the Growth Term Loan A proceeds net of a $0.3 million original issue discount. The Company also recorded a discount for the issuance of warrants with the Growth Term Loan A. The original issuance discount and warrant discount are being amortized, using the effective interest method, over the term of the Growth Term Loan A. Amortization expense was $46,727 and $148,859 for the three and nine months ended September 30, 2016, respectively, and $31,595 and $120,627 for the three and nine months ended September 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. The Company has recorded approximately $31,067 and $52,377 of deferred financing costs net of the related debt in the accompanying condensed balance sheets as of September 30, 2016 and December 31, 2015, respectively, in accordance with ASU 2015-03, which was adopted on January 1, 2016. Deferred financing cost amortization expense was $6,689 and $21,310 and $4,523 and $22,353 for the three and nine months ended September 30, 2016 and 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. In addition, in connection with the Growth Term Loan A, the Company issued preferred stock warrants to the lenders exercisable for 2,512,562 shares of Series E redeemable convertible preferred stock (“Series E Stock”) at a price of $0.2189 per share. Upon completion of the Company’s IPO in May 2015, the warrants were automatically converted to common stock warrants exercisable for up to 23,396 shares of common stock at an exercise price of $23.51 per share. The warrants expire on August 22, 2024. The final fee premium relating to the Growth Term Loan B of $237,500 is being amortized to interest expense, using the effective interest method, over the term of the Growth Term Loan B. In connection with the funding of the Growth Term Loan B, in March 2016, the Company issued Oxford Finance LLC a common stock warrant exercisable for 45,307 shares of common stock at an exercise price of $2.759 per share, and the warrant issued to Silicon Valley Bank automatically became exercisable for an additional 5,317 shares of common stock at an exercise price of $23.51 per share in accordance with the terms of the Growth Term Loan. The fair value of the discount of $122,460, was calculated using the Black-Scholes option pricing model at March 31, 2016. The warrant discount is being amortized to interest expense, using the effective interest method, over the term of the Growth Term Loan B. Amortization for the three and nine months ended September 30, 2016 was $18,918 and $40,838, respectively. There was no amortization for the three and nine months ended September 30, 2015 on Growth Term Loan B discount because the Growth Term Loan B was not outstanding during those periods. The principal repayments due under the term loan as of September 30, 2016, are as follows: 2016 $ 1,513,915 2017 6,389,782 2018 5,163,822 Total Growth Term Loan payments 13,067,519 Less discount and deferred financing costs (329,708 ) Plus final fee premium 419,256 Total Growth Term Loan, net $ 13,157,067 Convertible Notes On December 30, 2014, the Company entered into two, separate subordinated convertible promissory note agreements (the “Note Agreements”). The Note Agreements provided that upon a qualified equity financing, pursuant to which the Company raised either through a qualified IPO of common stock or through a qualifying private placement of convertible preferred stock, gross offering proceeds of at least $20,000,000 from the sale of shares to new investors, the outstanding principal amount and all accrued but unpaid interest under convertible notes issued pursuant to the Note Agreements would automatically convert into shares of common stock or preferred stock, whichever was sold in the offering. The number of shares into which the convertible notes were convertible was equal to the outstanding principal and accrued interest divided by the price per share paid by investors purchasing such newly issued equity securities. Draws under the first Note Agreement in February, March and April 2015 totaled $4.5 million. There were no draws under the second Note Agreement prior to the Company’s IPO in May 2015. The Company recorded a $741,828 discount for the estimated fair value of warrants issued in connection with the debt. Amortization of the Note Agreement discount and deferred financing fees associated with the Note Agreements was $0 and $90,222 for the three and nine months ended September 30, 2015, respectively, which was included in interest expense in the accompanying condensed statements of operations. Settlement of Convertible Debt upon IPO Closing Upon the initial closing of the Company’s IPO in May 2015, all outstanding principal and accrued interest was settled by issuing 324,591 shares of common stock valued at the IPO price of $14.00 for a total of $4.5 million. The Company evaluated the terms of the Note Agreements at inception and concluded that the convertible notes issued thereunder should be accounted for as share settled debt as they fall within the scope of ASC Topic 480, Distinguishing Liabilities from Equity

Other Agreements

Other Agreements	9 Months Ended
	Sep. 30, 2016
Other Agreements [Abstract]
Other Agreements	Note 9. Other Agreements NuvoGen Obligation The Company entered into an asset purchase agreement in 2001, as amended, with NuvoGen Research, LLC (“NuvoGen”) to acquire certain intellectual property from NuvoGen. The Company accounted for the transaction as an asset acquisition. However, as the intellectual property was determined to not have an alternative future use, the upfront consideration was expensed. In exchange for the intellectual property, the Company issued to NuvoGen 5,587 740,000 6 15,000,000 543,750 800,000 400,000 5 The Company recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, the Company’s estimate of its effective borrowing rate for similar obligations. Unamortized debt discount was $127,518 and $283,621 at September 30, 2016 and December 31, 2015, respectively. Discount accreted during the three and nine months ended September 30, 2016 was $51,636 and $156,103, respectively, and $51,481 and $229,232, during the three and nine months ended September 30, 2015, respectively. Pursuant to the closing of the Growth Term Loan A in August 2014 (see Note 8), the Company agreed to accelerate certain minimum payments pursuant to the asset purchase agreement and NuvoGen agreed to terminate its security interest in the originally pledged patents and trademarks. Remaining minimum payments that were otherwise due for 2014, 2015 and the first quarter of 2016, amounting to $868,750 The remaining payments due to NuvoGen at September 30, 2016, are, minimally, as follows, although actual payments could be significantly more than provided in the table in 2018 and beyond to the extent that 6% of revenue exceeds $400,000: 2016 $ 181,250 2017 800,000 2018 400,000 2019 400,000 2020 400,000 2021 and beyond 6,698,743 Total NuvoGen obligation payments 8,879,993 Less discount (127,518 ) Total NuvoGen obligation, net $ 8,752,475 Illumina, Inc. Agreement In October 2014, the Company entered into a development and component supply agreement with Illumina, Inc. for the development and worldwide commercialization by the Company of up to two complete diagnostic gene expression profiling tests for use with Illumina’s diagnostic instruments, using components supplied by Illumina. The Company refers to these diagnostic gene expression profiling tests as in vitro diagnostic (“IVD”) test kits. The IVD test kits originally could be used in up to two discrete testing fields chosen by the Company, one or both of which could relate to oncology for breast, lung, lymphoma or melanoma tumors, and up to one of which could relate to transplant, chronic obstructive pulmonary disease, or immunology/autoimmunity. The Company provided notice to Illumina of its first testing selection during the quarter ended March 31, 2015. The Company is in discussions with Illumina regarding a potential extension of the original October 2016 deadline to select a second field. In the fourth quarter of 2015, the Company and Illumina agreed to a development plan for the development and regulatory approval of the selected IVD test kit, following which the Company paid Illumina a $100,000 fee. Illumina has agreed to provide development and regulatory support as part of the plan. The Company is also required to pay Illumina up to $ 1.0 The agreement will expire on the earlier of October 2019 The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy Invetech PTY Ltd. Agreement In September 2015, the Company entered into a development and professional services agreement with Invetech PTY Ltd. (“Invetech”), for the conduct of research and development of a next generation automated sample library preparation instrument. This instrument is to be a low volume throughput version of the Company’s existing HTG EdgeSeq system technology and is being referred to as Project JANUS. The agreement requires the execution of a development plan for each stage of the project. Upon full execution and delivery of each development plan, the Company will pay Invetech development fee installments for that development plan. Stage 0 was completed during the second half of 2015. In July 2016, the Company entered into an amendment with Invetech, extending and concluding Stage 1.1 through the end of July 2016 and further suspending Invetech’s project development activities currently in process until the Company makes a decision to resume further external development efforts. Resumption of the external development effort is not expected until 2017 and will depend upon the prioritization of all of the Company’s development programs. The Invetech agreement remains in effect through completion of all tasks and the Company’s acceptance of all deliverables under each development plan unless terminated earlier as provided for in the agreement. Research and development expense included in the condensed statements of operations relating to Invetech development fee installments was $287,100 and $2,310,758 for the three and nine months ended September 30, 2016, respectively, and $150,000 for both the three and nine months ended September 30, 2015. Life Technologies Corporation Agreement In March 2016, the Company entered into an Authorization, Supply and Regulatory Authorization Agreement with Life Technologies Corporation (“LTC”), a wholly owned subsidiary of Thermo Fisher Scientific, Inc., for the development and worldwide commercialization by the Company of up to five RNA-based next generation sequencing panels (“HTG Assays”) for use with LTC’s sequencing instruments and components supplied to end-users by LTC. Pursuant to the agreement, the Company has agreed to obtain its requirements for certain components to be used in the development of HTG Assays from LTC. In March 2016, the Company purchased approximately $250,000 of LTC products and equipment in accordance with this agreement. LTC has agreed to provide support in the Company’s efforts to obtain regulatory approval of the HTG Assays. The Company is required to pay LTC a milestone payment in the mid-six figure dollar range upon certain regulatory achievements for each HTG Assay. In addition, the Company has agreed to pay LTC a single digit percentage royalty on net sales of any HTG Assays that the Company commercializes pursuant to the agreement. No milestone or royalty payments have been accrued or made pursuant to this agreement as of September 30, 2016. Absent early termination, the initial term of the agreement will expire in March 2021 and thereafter will automatically renew for additional two year terms for as long as the Company continues to develop or sell HTG Assays. Either party may terminate the agreement by written notice delivered to the other party at least 60 days prior to the expiration of any then-current term. Either party may also terminate the agreement (a) upon the other party’s material breach that remains uncured for 30 days, (b) upon the other party’s bankruptcy or (c) upon written notice in the event the party providing notice reasonably determines that continued performance under the agreement would violate any regulatory law, or any other applicable law or regulation or U.S. Food and Drug Administration (“FDA”) guidance. Bristol-Myers Squibb Agreement In May 2016, the Company entered into a Collaboration Agreement with Bristol-Myers Squibb (“BMS”) for the development, in collaboration with BMS, of two custom assays based on the Company’s HTG EdgeSeq technology. Following development of each custom assay, at BMS’s request, the Company may also perform sample processing services using such custom assay(s) and/or supply the custom assay(s) to BMS or its third-party subcontractors. Additional custom assay development related to immuno-oncology research may be undertaken pursuant to the agreement in accordance with a mutually acceptable work plan, which is incorporated by written amendment. BMS paid an initial non-refundable, non-creditable program set-up fee, and has agreed to pay an annual non-refundable, non-creditable project management fee in quarterly installments, as well as a fee for each custom assay developed. Each such fee was or is in the low six-figure range. At BMS’s request, custom assay kits will be supplied and sample processing services will be performed by the Company. The agreement will expire on May 11, 2019 or, if a project is then ongoing, the date of delivery of the final report for such project. Either party may terminate the agreement upon the other party’s material breach or default in the performance of a material obligation under the agreement or if certain warranties or representations are untrue in any material respect (either a “Default”) and such Default remains uncured for 60 days or such longer period if the Default cannot be cured within 60 days. BMS may terminate a project upon 90 days’ prior written notice to the Company. The agreement is a multiple-element arrangement under ASC 605-25, Revenue Recognition – Multiple-Element Arrangements Each custom assay development service has three phases and each phase comprises multiple deliverables. Completion of all three phases is required for BMS to derive benefit from the respective deliverables; therefore, the three phases of a custom assay’s development will be combined as one unit of accounting for revenue recognition purposes. Under ASC 605-25, fixed and determinable contract consideration is allocated to the deliverables with stand-alone value, and revenue is recognized for each such deliverable according to the method appropriate for each deliverable. All of the fixed and determinable contract consideration will be allocated to one deliverable, which is the research and development services culminating in the delivery of two custom assays. The quarterly project management fees and the initial set-up fee will be recognized as the custom assay development services are performed on a proportional performance basis. Each custom assay development fee will also be recognized on a proportional performance basis as these services are provided, which is consistent with the Company’s policy for deliverables or units of accounting that include milestones. Because they are contingent upon completion of each individual phase of the design project and the decision by BMS to proceed to the next phase and therefore are considered to be substantive milestones, the amount recognized will be limited to that which BMS is contractually obligated to pay upon completion of that phase. For the three and nine months ended September 30, 2016, $128,630 and $158,192, respectively, was recognized as service revenue under the agreement and $160,106 was recognized as deferred revenue as of September 30, 2016.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Loss per Share	Note 10. Net Loss Per Share Net loss per share attributable to common stockholders is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Outstanding stock options, warrants and convertible preferred stock have not been included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Numerator: Net loss $ (6,488,442 ) $ (5,157,663 ) $ (20,366,469 ) $ (15,698,139 ) Accretion of stock issuance costs — — — (35,046 ) Accretion of discount on Series E warrants — — — (127,616 ) Series E and D, Convertible Preferred Stock dividends — — — (1,165,932 ) Net loss attributable to common stockholders $ (6,488,442 ) $ (5,157,663 ) $ (20,366,469 ) $ (17,026,733 ) Denominator: Weighted-average common shares outstanding-basic and diluted 7,053,010 6,829,687 6,985,924 3,735,852 Net loss per share attributable to common stockholders, basic and diluted $ (0.92 ) $ (0.76 ) $ (2.92 ) $ (4.56 ) The following outstanding options and warrants were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2016 2015 Options to purchase common stock 1,200,644 590,139 Common stock warrant 219,723 170,587 Restricted stock units 350,499 27,500

Warrants

Warrants	9 Months Ended
	Sep. 30, 2016
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 11. Warrants In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock. On August 22, 2014, in connection with the Company’s entry into the Growth Term Loan, the Company issued to the lenders warrants exercisable for an aggregate of 2,512,562 shares of Series E stock at a price of $0.2189 per share. The warrants provide for cashless exercise at the option of the holders, and also contain provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. In connection with the closing of the Company’s IPO in May 2015, the warrants became exercisable for an aggregate of 23,396 shares of common stock at an exercise price of $23.51 per share. The warrants expire by their terms on August 22, 2024, provided that the warrants will be automatically exercised on a cashless basis upon expiration if not previously exercised if the fair market value of a share of the common stock exceeds the per share exercise price. In connection with the funding of the Growth Term Loan B, in March 2016 the Company issued Oxford Finance LLC a common stock warrant exercisable for 45,307 shares of common stock at an exercise price of $2.759 per share, and the warrant issued to Silicon Valley Bank automatically became exercisable for an additional 5,317 shares of common stock at an exercise price of $23.51 per share in accordance with the terms of the Growth Term Loan (see Note 8). On December 30, 2014, in connection with the Company’s Note Agreements (see Note 8) the Company agreed to issue warrants (the “Convertible Note Warrants”) exercisable for an aggregate of 9,311,586 shares of Series E Stock at a price of $0.2189 per share, for aggregate consideration of $1,354. The Convertible Note Warrants were issued on January 15, 2015. The warrants provide for cashless exercise at the option of the holders, and also contain provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. In connection with the closing of the Company’s IPO in May 2015, the Convertible Note Warrants became exercisable for an aggregate of 144,772 shares of common stock at the IPO price of $14.00 per share. The Convertible Note Warrants expire by their terms on January 15, 2022. As the Convertible Note Warrants were issued in conjunction with and in order to establish a lending facility commitment, they were being accounted for as a debt discount to be amortized over the life of the Note Agreements using the effective interest method and as a warrant liability, at fair value, as they were indexed to shares that could be redeemed for cash outside the control of the Company. The Company’s previously outstanding Series C-1 preferred stock warrants expired upon closing of the IPO as they were not exercised prior to or contemporaneously with the closing of the IPO. As of May 11, 2015, 1,290,350 Series C-1 preferred stock warrants were forfeited and cancelled as they were not exercised prior to the IPO. In connection with the closing of the Company’s IPO in May 2015, then outstanding Series C-2 preferred stock warrants became exercisable for an aggregate of 1,488 shares of common stock at an exercise price of $24.23 per share. These warrants expired by their terms and without exercise in December 2015. In connection with the closing of the Company’s IPO in May 2015, the Company issued an aggregate of 6,729 shares of common stock to the holders of Series D preferred stock warrants, and received aggregate cash consideration for such exercise of $1,752. The following table shows the warrants outstanding by series as of September 30, 2016 and December 31, 2015. Series of Warrants Shares of Common September 30, 2016 Shares of Common Warrants at December 31, 2015 Exercise Price/Share Expiration Date Series E redeemable convertible preferred stock warrants 28,713 23,396 23.51 2024 Convertible note warrants 144,772 144,772 14.00 2022 Common stock warrants 931 931 6.45 2019 Common stock warrants 45,307 — 2.76 2026 During the nine months ended September 30, 2015 the Company recorded a loss of $239,683 on the change in fair value of the preferred stock and convertible note warrants. The fair value of all preferred stock and convertible note warrants was updated prior to conversion at IPO, with the fair value change being charged to loss from change in stock warrant valuation in the condensed statements of operations. There was no similar loss recorded for the three months ended September 30, 2015 and the three and nine months ended September 30, 2016. The preferred stock warrant liability for outstanding Series C-2, Series D and Series E warrants was reclassified to additional paid-in-capital and recorded as common stock warrants upon the closing of the Company’s IPO. As such, the fair value of the preferred stock warrant liability was $0 at both September 30, 2016 and December 31, 2015.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Redeemable Convertible Preferred Stock	Note 12. Redeemable Convertible Preferred Stock On February 4, 2014, the Company entered into the Series E Preferred Stock and Warrant Purchase Agreement (the “Series E Agreement”) authorizing the sale and issuance of up to 99,132,024 shares of its Series E Stock for $0.2189 per share and warrants (the “Series E Warrants”) to purchase up to an aggregate of 33,044,008 shares of Series E Stock at an exercise price of $0.001 per share. Pursuant to the Series E Agreement, up to 49,566,012 shares of Series E Stock together with Series E Warrants to purchase up to an aggregate of 16,522,004 shares of Series E Stock would be offered at one or more closings of a first tranche and the remainder of which would be offered in a second tranche. In connection with the Series E Preferred Agreement, the Company’s authorized shares were increased to 600,000,000 shares of Common Stock and 472,083,383 shares of Preferred Stock. On February 4, 2014 the Company issued 34,099,476 shares of Series E Stock pursuant to the Series E Agreement at a price per share of $0.2189 per share. Along with the shares of Series E Stock, one Series E Warrant was issued for every three shares of Series E Stock purchased with a purchase price of $0.0001 per Series E Warrant and an exercise price of $0.001 per share of Series E Stock for a total of 11,366,486 Series E Warrants. Each Series E Stock purchaser was required to exercise the Series E Warrant in a simultaneous transaction with the purchase of shares of Series E Stock. The Company received aggregate gross proceeds of $7,476,879 from these issuances. On March 31, 2014, pursuant to a rights offering, the Company issued 354,062 shares of Series E Stock pursuant to the Series E Agreement at a price per share of $0.2189 per share. Along with the shares of Series E Stock, one Series E Warrant was issued for each three shares of Series E Stock purchased with a purchase price of $0.0001 per Series E Warrant and an exercise price of $0.001 per share of Series E Stock for a total of 118,017 Series E Warrants. Each Series E Stock purchaser was required to exercise the Series E Warrant in a simultaneous transaction with the purchase of shares of Series E Stock. The Company received aggregate proceeds of $77,634 for these issuances. The Series E Agreement provided for a second tranche on or before November 30, 2014, contingent upon the achievement of certain milestones. It was determined that, given the nominal strike price of the Series E Warrants and the fact that the Series E Preferred Warrants were required to be exercised immediately upon issuance, the per share value of the Series E Warrants would be similar to the effective per share value of the Series E Stock, or $0.1645 per share. The second closing under the Series E Agreement, originally scheduled to occur on or before November 31, 2014, was replaced by an alternative financing in the form of subordinated convertible notes as discussed further in Note 8. The Series A/B/C/D Stock and Series E Stock had a par value of $0.001 per share. The Series D Stock and Series E Stock liquidation preference was equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared. The Company has historically accreted up to the redemption amount and not the liquidation value, because additional amounts due under the liquidation rights was not considered probable at initial recording or as of the Company’s initial public offering in May 2015 or at December 31, 2014. The shares of Series A/B/C/D Stock and Series E Stock historically had the right to redemption of their respective class of shares on a date beginning not prior to February 2019 (the “Series E Preferred Stock Redemption Date”). In order to affect each respective redemption, the holders of at least 60% of the voting power of the then outstanding shares of Series D Stock or Series E Stock needed to vote in favor of a Series D or Series E Stock redemption and provide written notice to the Company at lease sixty days prior to the Series E Preferred Stock Redemption Date of such election. The holders of at least a majority in the voting power of the then outstanding shares of the Series A/B/C Stock could then vote in favor of a Series A/B/C Stock redemption, respectively. The holders of at least 66 2/3% of the voting power of the then outstanding shares of Series A Redeemable Convertible Preferred Stock (“Series A Stock”) could then vote in favor of a Series A Stock redemption. The Series D Stock and Series E Stock redemption value was equal to the Series D Stock and Series E Stock original issue price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) plus all dividends declared but unpaid thereon together with any accruing dividends accrued but unpaid thereon, whether or not declared with respect to such shares. The Series A/B/C/D and Series E Stock redemption value was equal to the respective series original issue price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) plus all accrued and unpaid dividends with respect to such shares. If the Company did not have sufficient funds or other assets legally available to redeem all shares to be redeemed at any redemption date, it was to redeem as applicable (i) pro rata to Series E Stock, until all shares were redeemed, (ii) pro rata to Series D Stock until all shares were redeemed, (iii) pro rata to Series C Stock, until all shares were redeemed, (iv) pro rata to Series A Stock and Series B Stock, until all shares were redeemed. If any shares to be redeemed remained outstanding, the Company was to redeem the remaining shares in accordance with the previous sentence as soon as sufficient funds were legally available. Due to the redemption feature, the preferred shares were historically recorded as mezzanine equity. Preferred Shares Carrying Value at 5/11/15 Preferred Shares Before IPO Common Shares After IPO Series A Stock $ 1,403,007 1,292,084 38,973 Series B Stock 2,100,149 6,789,712 75,835 Series C-1 Stock 4,569,063 13,242,612 191,406 Series C-2 Stock 2,225,619 9,948,331 93,757 Series D Stock 30,370,273 140,252,678 1,305,984 Series E Stock 7,879,873 45,989,722 428,237 Carrying value, excluding dividends $ 48,547,984 217,515,139 2,134,192 Series D Stock and Series E Stock cumulative dividends 8,808,065 — 374,632 Total $ 57,356,049 217,515,139 2,508,824 As of the Company’s IPO in May 2015, Series A Stock, Series B Stock, Series C-1 Stock, Series C-2 Stock, Series D Stock and Series E Stock conversion ratios were 0.030, 0.011, 0.014, 0.009, 0.009 and 0.009, respectively, after consideration of the one-for-107.39 reverse split. When converted at May 11, 2015, all of the outstanding preferred shares and cumulative accrued dividends on Series D Stock and Series E Stock were converted into 2,134,192 and 374,632 shares of common stock, respectively. The Company has historically accounted for the Series E Warrants as liabilities as such warrants were indexed to shares that could be redeemed for cash outside the control of the Company. The Company allocated the total proceeds first to the Series E Warrants based on their fair value of approximately $1,890,000 and the remainder amounting to approximately $5,665,000 of the proceeds allocated to the Preferred Shares. The fair value of the Series E Warrants was estimated to approximate the fair value of the Series E Stock because of their nominal price. The amount allocated to the Series E Warrants represented a discount to the Preferred Shares and was being accreted using the effective interest method up to the redemption amount from the respective issuance date to redemption date of five years. Accretion for the three and nine months ended September 30, 2016 was $0, and accretion for the three and nine months ended September 30, 2015 was approximately $0 and $128,000, respectively. Upon immediate exercise of the Series E Warrants, the amount recorded as warrant liability was reclassified to Preferred Shares, and issuance costs of $48,384, which had been allocated to the warrants were expensed. The Company was not accreting to the amount resulting from additional liquidation preference rights under the agreement because they were not considered probable at initial recording or at any point between then and May 2015 IPO. The Company additionally analyzed the issuance of Series E Warrants with the Series E Stock, noting there was no resulting beneficial conversion feature. Following the IPO, all outstanding warrants previously exercisable for preferred stock became exercisable for common stock. The previously reported warrant liability associated with the convertible warrants was applied to additional paid-in-capital. The Company’s Series D Stock and Series E Stock accrued cumulative dividends at 8% per annum on the original issue price of $0.2189, whether or not declared by the board of directors. In connection with the Company’s Growth Term Loan, the holders of both the Series D Stock and Series E Stock agreed to waive their rights to cash dividends. As a result, only a share dividend, based on the cumulative dividends divided by the original issue price, could be paid upon declaration by the board of directors or upon the automatic conversion of the Company’s Preferred Stock. Dividends were being accreted based on the number of days outstanding. All shares of Series D and Series E, together with accrued dividends, automatically converted into 374,632 shares of the Company’s common stock (on as converted method) in connection with the initial closing of the IPO on May 11, 2015.

Stockholders Equity

Stockholders Equity	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Stockholders' Equity	Note 13. Stockholders’ Equity Common Stock The Company amended its certificate of incorporation on May 11, 2015, to decrease the number of authorized shares of common stock from 600,000,000 to 200,000,000 shares. The 200,000,000 authorized shares of common stock have a par value of $0.001 per share. As of September 30, 2016, 7,060,269 and 7,058,873 shares were issued and outstanding, respectively. As of December 31, 2015, 6,845,638 and 6,844,242 shares were issued and outstanding, respectively. Preferred Stock Pursuant to the Company’s amended and restated certificate of incorporation, the Company is authorized to issue 10,000,000 shares of preferred stock, each having a par value of $0.001. The preferred stock may be issued from time to time in one or more series with the authorization of the Company’s board of directors, with such voting, conversion and other rights and preferences as the board of directors may determine. No shares of preferred stock have been issued to date. Stock-based Compensation 2014 Equity Incentive Plan As of September 30, 2016, there were 68,450 shares available for issuance under the Company’s 2014 equity incentive plan and options to purchase 1,200,644 shares of common stock were outstanding, including 571,800 options that were fully vested. As of September 30, 2016, there was total unrecognized compensation expense of $1,064,203 related to unvested stock options, which the Company expects to recognize over a weighted-average period of approximately 2.41 years. In April 2016, in connection with the severance of an employee, the Company accelerated the vesting of 8,957 unvested stock options, as well as the period following termination whereby all of the employee’s vested stock options, including those accelerated as part of the severance agreement, could be exercised for a two year period from the termination date. As a result of this modification, the Company recorded incremental stock-based compensation expense of approximately $0 and $13,500 for the three and nine months ended September 30, 2016. A summary of the Plans’ stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2015 736,645 $ 4.18 7.5 $ 947,794 Granted 548,400 2.47 Exercised (4,712 ) 2.15 Forfeited (79,689 ) 4.90 Balance at September 30, 2016 1,200,644 $ 3.36 7.9 $ 48,246 Vested and expected to vest at September 30, 2016 1,111,699 $ 3.37 7.8 $ 48,086 Exercisable at September 30, 2016 571,800 $ 3.44 6.5 $ 40,266 As of September 30, 2016, there were 350,499 restricted stock units (“RSUs”) unvested and outstanding. Unrecognized compensation expense related to the remaining RSUs was $730,655 at September 30, 2016, which the Company expects to recognize over a weighted-average remaining service period of one year. A summary of the Plans’ RSU activity is as follows: Restricted Stock Units (RSU) Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2015 27,500 $ 5.45 Granted 379,761 2.44 Vested (36,762 ) 2.90 Forfeited (20,000 ) 2.46 Balance at September 30, 2016 350,499 $ 2.43 Vested and expected to vest at September 30, 2016 333,117 $ 2.43 The stock-based compensation expense recorded in the condensed statements of operations for the three and nine months ended September 30, 2016 was $229,918 and $552,054, respectively, and $77,239 and $223,787 for the three and nine months ended September 30, 2015, respectively. 2014 Employee Stock Purchase Plan In April 2015, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan (“ESPP”), which became effective in May 2015. Initially, the ESPP authorized the issuance of up to 110,820 shares of common stock pursuant to the purchase rights granted to the Company’s employees or to employees of the Company’s designated affiliates. The number of shares of common stock reserved for issuance automatically increased in accordance with the plan by 68,442 on January 1, 2016. The ESPP enables participants to contribute up to 15% of such participant’s eligible compensation during a defined period (not to exceed 27 months) to purchase common stock of the Company. The purchase price of common stock under the ESPP will be the lesser of: (i) 85% of the fair market value of the Company’s common stock on the first date of an offering or (2) 85% of the fair market value of a share of the Company’s common stock on the date of purchase. As of September 30, 2016, 39,978 shares of stock have been purchased under the ESPP since its initiation in January 2016 at a weighted average price per share of $2.54.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Severance Agreements The Company has entered into employment agreements or other arrangements with certain executive officers which provide salary continuation payments, bonuses and, in certain instances, the acceleration of the vesting of certain equity awards to individuals in the event that the individual is terminated other than for cause, as defined in the applicable agreements or arrangements. Indemnification Agreements In the course of operating its business, the Company has entered into, and continues to enter into, separate indemnification agreements with the Company’s directors and executive officers, in addition to the indemnification provided for in the Company’s amended and restated bylaws. These agreements may require the Company to indemnify its directors and executive officers for certain expenses incurred by a director executive officer in any action or proceeding arising out of their services as one of the Company’s directors or executive officers. Leases The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona. The Company amended its facilities leases in August 2015 to extend the terms for approximately five years and to undergo leasehold improvements to expand and improve its existing research, development, operations and administration office facilities. The lease amendment includes an increase of $804,000 in total monthly rent over the remaining term of the leases. The landlord constructed certain leasehold improvements as an incentive to extend the leases. The total cost of the improvements constructed by the landlord of $710,000 was capitalized when the construction was completed in February 2016, and is being depreciated over the remaining term of the lease agreement. The incentive of $710,000 has been recognized as deferred rent within other current liabilities and other liabilities on the condensed balance sheets, and is being accreted at $11,833 per month over the lease term as a reduction of rent expense. As a result of the amendments, the Company’s remaining minimum real estate lease payments before common area maintenance charges as of September 30, 2016 are as follows: 2016 $ 126,987 2017 510,125 2018 512,533 2019 514,977 2020 517,457 2021 and beyond 43,139 $ 2,225,218 As of September 30, 2016, the Company also has capital lease commitments consisting of approximately $148,900 of leases for computer equipment varying in length from 36 to 48 months and an equipment financing arrangement of approximately $36,000 with a vendor that expires in December 2017 that have not been included in the minimum lease payments schedule above. Merck Non-Exclusive License Agreement In June 2012, the Company entered into a non-exclusive license agreement with Merck Sharp & Dohme Co. (“Merck”) whereby the Company agreed to sublicense certain intellectual property related to breast cancer biomarkers with the intent to develop, manufacture and commercialize a diagnostic test utilizing this technology. The Company agreed to pay Merck certain contingent milestone payments between $50,000 and $1,000,000 and future royalties of 3%-6% of sales derived from such products developed that utilize the licensed technology. No amounts have been accrued or paid under this agreement as the Company has not achieved any of the milestone targets or developed any products that utilize the licensed technology. Product Warranty The following is a summary of the Company’s general product warranty liability: Nine Months Ended September 30, 2016 2015 Beginning balance $ 20,213 $ — Cost of warranty claims (67,663 ) (545 ) Warranty accrual 83,745 17,225 Ending balance $ 36,295 $ 16,680 Warranty accrual is included in accrued liabilities in the condensed balance sheets as of September 30, 2016 and December 31, 2015. Expense relating to the recording of this accrual is recorded in cost of revenue within the condensed statements of operations.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as the realization of the net deferred tax assets is uncertain. As a result, the Company has not recorded any federal or state income tax benefit in the statements of operations; however, state income tax expense has been recorded for state minimum taxes. The Company periodically reviews its filing positions for all open tax years in all U.S. federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation process, if any. The term “more likely than not” means a likelihood of more than 50 percent. Otherwise, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the “more likely than not” criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. The Company has not identified any uncertain tax positions at September 30, 2016 or December 31, 2015. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at September 30, 2016 and December 31, 2015, respectively, and has not recognized interest or penalties of significance during the three and nine months ended September 30, 2016 and 2015, respectively, since there are no material unrecognized tax benefits. Management believes no material change to the amount of unrecognized tax benefits will occur within in the next 12 months. The Company has established a valuation allowance against the entire tax asset. As a result, the Company does not recognize any tax benefit until it is in a taxpaying position and, therefore, more likely to realize the tax benefit. Past and subsequent equity offerings by the Company, and other transactions that have an impact on the Company’s ownership structure, may trigger Sections 382 and 383 provisions of the Internal Revenue Code of 1986, as amended, on special limitations on net operating losses and credits following ownership change. Such limitations may limit or eliminate the potential future tax benefit to be realized by the Company from its accumulated net operating losses and research and development credits.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect the accounts of the Company as of September 30, 2016. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The unaudited condensed balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 24, 2016.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.
Going Concern	Going Concern The Company implemented the criteria of Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The Company will need to raise additional capital to fund its operations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. If sufficient additional capital is not available as and when needed, the Company may have to delay, scale back or discontinue one or more product development programs, curtail its commercialization activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize independently, cease operations altogether, pursue an acquisition of the Company at a price that may result in up to a total loss on investment for its stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all assets.
Change in Accounting Principle	Change in Accounting Principle In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-03, Interest – Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long-lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, available‑for‑sale debt securities and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three and nine months ended September 30, 2016 and 2015 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Instruments $ 5,846 $ 338,231 $ 88,146 $ 597,426 Consumables 500,219 635,725 1,595,236 1,752,314 Total product sales $ 506,065 $ 973,956 $ 1,683,382 $ 2,349,740 The Company’s top three customers accounted for 27%, 24% and 9% of the Company’s revenue for the three months ended September 30, 2016, compared with 26%, 16% and 12% for the three months ended September 30, 2015. The top three customers accounted for 38%, 14% and 7% of the Company’s revenue for the nine months ended September 30, 2016, compared with 29%, 10% and 6% of the Company’s revenue for the nine months ended September 30, 2015. The top two customers accounted for approximately 59% and 11% of the Company’s net accounts receivable as of September 30, 2016, compared with approximately 32% and 25% as of December 31, 2015. The Company currently relies on a single supplier to supply a subcomponent used in the HTG Edge and HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of HTG Edge and HTG EdgeSeq systems, which in turn would materially affect the Company’s ability to generate revenue.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers The revised revenue standard is effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its financial statements and has not yet determined the method by which it will adopt the standard. In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-09, Share-Based Payment: Simplifying the Accounting for Share-Based Payments In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients . will have the same effective date and transition requirements as ASU 2014‑09. The Company is currently evaluating the effect the adoption of ASU 2016-12 will have on its financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Product Revenue from Sale of Instruments and Consumables	The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three and nine months ended September 30, 2016 and 2015 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Instruments $ 5,846 $ 338,231 $ 88,146 $ 597,426 Consumables 500,219 635,725 1,595,236 1,752,314 Total product sales $ 506,065 $ 973,956 $ 1,683,382 $ 2,349,740

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the date indicated: September 30, December 31, 2016 2015 Raw materials $ 1,584,273 $ 1,274,840 Work in process 1,991 — Finished goods 948,974 1,210,780 Total gross inventory 2,535,238 2,485,620 Less inventory allowance (667,553 ) (284,319 ) $ 1,867,685 $ 2,201,301

Fair Value Instruments (Tables)

Fair Value Instruments (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2016 and December 31, 2015, respectively in the fair value hierarchy: Balance at September 30, 2016 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 4,897,198 $ — $ — $ 4,897,198 Investments available-for-sale at fair value U.S. government obligations $ 1,302,991 $ — $ — $ 1,302,991 U.S. government agency obligations $ — $ 3,582,980 $ — $ 3,582,980 Corporate debt securities $ — $ 6,211,169 $ — $ 6,211,169 Balance at December 31, 2015 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 3,290,490 $ — $ — $ 3,290,490 Investments available-for-sale at fair value U.S. government obligations $ 3,298,014 $ — $ — $ 3,298,014 U.S. government agency obligations $ — $ 14,589,378 $ — $ 14,589,378 Corporate debt securities $ — $ 12,918,016 $ — $ 12,918,016

Available for Sale Securities (

Available for Sale Securities (Tables)	9 Months Ended
	Sep. 30, 2016
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The following is a summary of the Company’s available-for-sale securities at September 30, 2016 and December 31, 2015: September 30, 2016 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities and obligations of U.S. government agencies $ 4,884,459 $ 1,511 $ — $ 4,885,970 Corporate debt securities 6,213,001 $ — (1,831 ) 6,211,170 Total available-for-sale securities $ 11,097,460 $ 1,511 $ (1,831 ) $ 11,097,140 December 31, 2015 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities and obligations of U.S. government agencies $ 17,914,136 $ — $ (26,744 ) $ 17,887,392 Corporate debt securities 12,932,629 397 (15,010 ) 12,918,016 Total available-for-sale securities $ 30,846,765 $ 397 $ (41,754 ) $ 30,805,408
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities at September 30, 2016 are shown below. Under 1 Year 1 to 2 Years Total U.S. Treasury securities and obligations of U.S. government agencies $ 4,885,970 $ — $ 4,885,970 Corporate debt securities 6,211,170 — 6,211,170 Total available-for-sale securities $ 11,097,140 $ — $ 11,097,140
Summary of Debt Securities with Unrealized Losses	The following table shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of September 30, 2016: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses U.S. Treasury securities and obligations of U.S. government agencies $ — $ — $ — $ — $ — $ — Corporate debt securities 2,817,800 (1,831 ) — — 2,817,800 (1,831 ) Total available-for-sale securities with unrealized losses $ 2,817,800 $ (1,831 ) $ — $ — $ 2,817,800 $ (1,831 )

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net, consists of the following: September 30, December 31, 2016 2015 Office equipment $ 499,362 $ 257,296 Leasehold improvements 1,847,378 224,061 Laboratory and manufacturing equipment 3,445,446 2,442,191 Field equipment 131,096 180,355 Software 140,248 140,248 Construction in progress 145,063 175,501 6,208,593 3,419,652 Less: accumulated depreciation and amortization (2,541,646 ) (1,487,439 ) $ 3,666,947 $ 1,932,213

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consist of the following: September 30, December 31, 2016 2015 Employee compensation and benefits $ 756,501 $ 1,240,314 Employee compensation for future absences 160,183 154,107 Interest 93,413 77,917 Professional fees 63,480 140,385 Other 218,708 302,545 $ 1,292,285 $ 1,915,268

Debt Obligations (Tables)

Debt Obligations (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Principal Repayments Due Under Term Loan	The principal repayments due under the term loan as of September 30, 2016, are as follows: 2016 $ 1,513,915 2017 6,389,782 2018 5,163,822 Total Growth Term Loan payments 13,067,519 Less discount and deferred financing costs (329,708 ) Plus final fee premium 419,256 Total Growth Term Loan, net $ 13,157,067

Other Agreements (Tables)

Other Agreements (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Schedule of Remaining Payments Due	The remaining payments due to NuvoGen at September 30, 2016, are, minimally, as follows, although actual payments could be significantly more than provided in the table in 2018 and beyond to the extent that 6% of revenue exceeds $400,000: 2016 $ 181,250 2017 800,000 2018 400,000 2019 400,000 2020 400,000 2021 and beyond 6,698,743 Total NuvoGen obligation payments 8,879,993 Less discount (127,518 ) Total NuvoGen obligation, net $ 8,752,475

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Numerator: Net loss $ (6,488,442 ) $ (5,157,663 ) $ (20,366,469 ) $ (15,698,139 ) Accretion of stock issuance costs — — — (35,046 ) Accretion of discount on Series E warrants — — — (127,616 ) Series E and D, Convertible Preferred Stock dividends — — — (1,165,932 ) Net loss attributable to common stockholders $ (6,488,442 ) $ (5,157,663 ) $ (20,366,469 ) $ (17,026,733 ) Denominator: Weighted-average common shares outstanding-basic and diluted 7,053,010 6,829,687 6,985,924 3,735,852 Net loss per share attributable to common stockholders, basic and diluted $ (0.92 ) $ (0.76 ) $ (2.92 ) $ (4.56 )
Outstanding Options and Warrants Excluded from Computation of Diluted Net Loss per Share	The following outstanding options and warrants were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2016 2015 Options to purchase common stock 1,200,644 590,139 Common stock warrant 219,723 170,587 Restricted stock units 350,499 27,500

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2016
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	The following table shows the warrants outstanding by series as of September 30, 2016 and December 31, 2015. Series of Warrants Shares of Common September 30, 2016 Shares of Common Warrants at December 31, 2015 Exercise Price/Share Expiration Date Series E redeemable convertible preferred stock warrants 28,713 23,396 23.51 2024 Convertible note warrants 144,772 144,772 14.00 2022 Common stock warrants 931 931 6.45 2019 Common stock warrants 45,307 — 2.76 2026

Redeemable Convertible Prefer34

Redeemable Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Preferred Stock	Preferred Shares Carrying Value at 5/11/15 Preferred Shares Before IPO Common Shares After IPO Series A Stock $ 1,403,007 1,292,084 38,973 Series B Stock 2,100,149 6,789,712 75,835 Series C-1 Stock 4,569,063 13,242,612 191,406 Series C-2 Stock 2,225,619 9,948,331 93,757 Series D Stock 30,370,273 140,252,678 1,305,984 Series E Stock 7,879,873 45,989,722 428,237 Carrying value, excluding dividends $ 48,547,984 217,515,139 2,134,192 Series D Stock and Series E Stock cumulative dividends 8,808,065 — 374,632 Total $ 57,356,049 217,515,139 2,508,824

Stockholders Equity (Tables)

Stockholders Equity (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Stock Option Plans Activity	A summary of the Plans’ stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2015 736,645 $ 4.18 7.5 $ 947,794 Granted 548,400 2.47 Exercised (4,712 ) 2.15 Forfeited (79,689 ) 4.90 Balance at September 30, 2016 1,200,644 $ 3.36 7.9 $ 48,246 Vested and expected to vest at September 30, 2016 1,111,699 $ 3.37 7.8 $ 48,086 Exercisable at September 30, 2016 571,800 $ 3.44 6.5 $ 40,266
Summary of RSU Plans Activity	A summary of the Plans’ RSU activity is as follows: Restricted Stock Units (RSU) Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2015 27,500 $ 5.45 Granted 379,761 2.44 Vested (36,762 ) 2.90 Forfeited (20,000 ) 2.46 Balance at September 30, 2016 350,499 $ 2.43 Vested and expected to vest at September 30, 2016 333,117 $ 2.43

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Minimum Real Estate Lease Payments Before Common Area Maintenance Charges	As a result of the amendments, the Company’s remaining minimum real estate lease payments before common area maintenance charges as of September 30, 2016 are as follows: 2016 $ 126,987 2017 510,125 2018 512,533 2019 514,977 2020 517,457 2021 and beyond 43,139 $ 2,225,218
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability: Nine Months Ended September 30, 2016 2015 Beginning balance $ 20,213 $ — Cost of warranty claims (67,663 ) (545 ) Warranty accrual 83,745 17,225 Ending balance $ 36,295 $ 16,680

Description of Business - Addit

Description of Business - Additional Information (Details) - Segment	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Significant Accounting Policies [Line Items]
Number of operating segments			1
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	15.00%	24.00%	11.00%	11.00%

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016USD ($)Customer	Sep. 30, 2015Customer	Sep. 30, 2016USD ($)Customer	Sep. 30, 2015Customer	Dec. 31, 2015USD ($)Customer
Significant Accounting Policies [Line Items]
Prior Period Reclassification Adjustment			$ 0
Accumulated deficit	$ 109,932,963		109,932,963		$ 89,566,494
Available cash, cash equivalents and investments in short term available-for-sale securities, amount	16,600,000		16,600,000
Current liabilities	9,801,121		9,801,121		6,319,610
Long-term liabilities	$ 6,902,379		$ 6,902,379		$ 7,737,586
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer	3	3	3	3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage	27.00%	26.00%	38.00%	29.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage	24.00%	16.00%	14.00%	10.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage	9.00%	12.00%	7.00%	6.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer			2		2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage			59.00%		32.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			11.00%		25.00%
Growth Term Loan
Significant Accounting Policies [Line Items]
Long-term liabilities	$ 6,900,000		$ 6,900,000
Deferred financing costs	$ 31,067		$ 31,067		$ 52,377

Basis of Presentation - Product

Basis of Presentation - Product Revenue from Sale of Instruments and Consumables (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Revenue Reconciling Item [Line Items]
Total product sales	$ 506,065	$ 973,956	$ 1,683,382	$ 2,349,740
Instruments
Segment Reporting Revenue Reconciling Item [Line Items]
Total product sales	5,846	338,231	88,146	597,426
Consumables
Segment Reporting Revenue Reconciling Item [Line Items]
Total product sales	$ 500,219	$ 635,725	$ 1,595,236	$ 1,752,314

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Inventory [Line Items]
Adjustments to provision for excess inventory, gross	$ 288,130	$ 76,799	$ 437,893	$ 330,088
Adjustments to provision for excess inventory net of inventory write down	$ 291,692	$ 62,872	383,234	273,752
Write off obsolete inventory			$ 54,659	$ 56,336
Minimum
Inventory [Line Items]
Period of time customers use to evaluate the Company’s equipment			90 days
Maximum
Inventory [Line Items]
Period of time customers use to evaluate the Company’s equipment			180 days

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 1,584,273	$ 1,274,840
Work in process	1,991
Finished goods	948,974	1,210,780
Total gross inventory	2,535,238	2,485,620
Less inventory allowance	(667,553)	(284,319)
Inventory, net	$ 1,867,685	$ 2,201,301

Fair Value Instruments - Financ

Fair Value Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	$ 4,897,198	$ 3,290,490
Investments Available-for-sale at Fair Value | U.S. Government Obligations
Asset included in:
Financial Assets	1,302,991	3,298,014
Investments Available-for-sale at Fair Value | U.S. Government Agency Obligations
Asset included in:
Financial Assets	3,582,980	14,589,378
Investments Available-for-sale at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	6,211,169	12,918,016
Level 1 | Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	4,897,198	3,290,490
Level 1 | Investments Available-for-sale at Fair Value | U.S. Government Obligations
Asset included in:
Financial Assets	1,302,991	3,298,014
Level 2 | Investments Available-for-sale at Fair Value | U.S. Government Agency Obligations
Asset included in:
Financial Assets	3,582,980	14,589,378
Level 2 | Investments Available-for-sale at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	$ 6,211,169	$ 12,918,016

Fair Value Instruments - Additi

Fair Value Instruments - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0	$ 0	$ 0

Available for Sale Securities -

Available for Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 11,097,460	$ 30,846,765
Gross Unrealized Gains	1,511	397
Gross Unrealized Losses	(1,831)	(41,754)
Fair Value (Net Carrying Amount)	11,097,140	30,805,408
U.S. Treasury Securities and Obligations of U.S. Government Agencies
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	4,884,459	17,914,136
Gross Unrealized Gains	1,511
Gross Unrealized Losses		(26,744)
Fair Value (Net Carrying Amount)	4,885,970	17,887,392
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	6,213,001	12,932,629
Gross Unrealized Gains		397
Gross Unrealized Losses	(1,831)	(15,010)
Fair Value (Net Carrying Amount)	$ 6,211,170	$ 12,918,016

Available for Sale Securities45

Available for Sale Securities - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Schedule Of Available For Sale Securities [Line Items]
Net unrealized holding gains (losses)	$ (2,836)	$ 12,993	$ 41,037	$ 4,754
Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Other-than-temporary impairment	$ 0		$ 0

Available for Sale Securities46

Available for Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 11,097,140
Fair Value (Net Carrying Amount)	11,097,140	$ 30,805,408
U.S. Treasury Securities and Obligations of U.S. Government Agencies
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	4,885,970
Fair Value (Net Carrying Amount)	4,885,970	17,887,392
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	6,211,170
Fair Value (Net Carrying Amount)	$ 6,211,170	$ 12,918,016

Available for Sale Securities47

Available for Sale Securities - Summary of Debt Securities with Unrealized Losses (Details)	Sep. 30, 2016USD ($)
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	$ 2,817,800
Under 1 Year, Gross Unrealized Losses	(1,831)
Total, Fair Value	2,817,800
Total, Gross Unrealized Losses	(1,831)
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	2,817,800
Under 1 Year, Gross Unrealized Losses	(1,831)
Total, Fair Value	2,817,800
Total, Gross Unrealized Losses	$ (1,831)

Summary Of Property and Equipme

Summary Of Property and Equipment (Details) - USD ($)	Sep. 30, 2016	Feb. 29, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Office equipment	$ 499,362		$ 257,296
Leasehold improvements	1,847,378	$ 710,000	224,061
Laboratory and manufacturing equipment	3,445,446		2,442,191
Field equipment	131,096		180,355
Software	140,248		140,248
Construction in progress	145,063		175,501
Total property and equipment, gross	6,208,593		3,419,652
Less: accumulated depreciation and amortization	(2,541,646)		(1,487,439)
Property and equipment, net	$ 3,666,947		$ 1,932,213

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 357,924	$ 174,390	$ 1,086,752	$ 473,799
Total costs of leased assets	$ 373,048		373,048		$ 146,213
Accumulated depreciation and amortization of leased assets			$ 188,179		$ 88,220

Summary of Accrued Liabilities

Summary of Accrued Liabilities (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Employee compensation and benefits	$ 756,501	$ 1,240,314
Employee compensation for future absences	160,183	154,107
Interest	93,413	77,917
Professional fees	63,480	140,385
Other	218,708	302,545
Total accrued liabilities	$ 1,292,285	$ 1,915,268

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details)	Dec. 30, 2014USD ($)Agreement	May 31, 2015USD ($)$ / sharesshares	Aug. 31, 2014USD ($)Institution$ / sharesshares	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Mar. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Aug. 31, 2015	Aug. 22, 2014USD ($)
Debt Obligations [Line Items]
Debt instrument, amortization expense						$ 156,103	$ 229,232
Amortization of warrant discount							127,616
Percentage of possible outcomes in debt note agreements issued		50.00%
Write off unamortized debt discount and deferred financing costs				$ 0	$ 0	0	705,217
Convertible Debt
Debt Obligations [Line Items]
Amortization of warrant discount					0		90,222
Growth Term Loan
Debt Obligations [Line Items]
Number of loan lending institutions | Institution			2
Final Payment Percentage										4.75%
Deferred financing costs				31,067		31,067			$ 52,377
Amortization of deferred financing costs				6,689	4,523	21,310	22,353
Growth Term Loan | Scenario Forecast One
Debt Obligations [Line Items]
prepayment fee Percentage										3.00%
Growth Term Loan | Scenario Forecast Two
Debt Obligations [Line Items]
prepayment fee Percentage										2.00%
Growth Term Loan | Scenario Forecast Three
Debt Obligations [Line Items]
prepayment fee Percentage										1.00%
Growth Term Loan A
Debt Obligations [Line Items]
Term loan payable											$ 11,000,000
Debt instrument, fixed rate			8.50%
Debt instrument, maturity date			Sep. 30, 2018
Debt issuance costs			$ 300,000
Debt instrument, amortization expense				46,727	31,595	148,859	120,627
Growth Term Loan A | Series E Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share | shares			2,512,562
Convertible preferred stock, price per share | $ / shares			$ 0.2189
Warrants issued to acquire shares | shares		23,396
Warrants exercise price | $ / shares		$ 23.51
Warrant Expiration Date			Aug. 22, 2024
Growth Term Loan B
Debt Obligations [Line Items]
Term loan payable			$ 5,000,000
Debt instrument, fixed rate			8.75%
Debt instrument, maturity date			Sep. 30, 2018
Debt instrument, amortization expense				18,918	$ 0	40,838	$ 0
Investment income, amortization of premium						237,500
Fair value of warrants								$ 122,460
Growth Term Loan B | Oxford Finance LLC
Debt Obligations [Line Items]
Warrants exercise price | $ / shares								$ 2.759
Financial institution warrant issued, share | shares								45,307
Growth Term Loan B | Silicon Valley Bank
Debt Obligations [Line Items]
Warrants exercise price | $ / shares								$ 23.51
Financial institution warrant issued, share | shares								5,317
Convertible Notes
Debt Obligations [Line Items]
Fair value of warrants				$ 741,828		$ 741,828
Number of convertible promissory note agreements | Agreement	2
Conversion of stock, shares converted | shares		324,591
Conversion price per share | $ / shares		$ 14
Conversion of stock, amount converted		$ 4,500,000
Convertible Notes | Private Placement | Minimum
Debt Obligations [Line Items]
Proceeds from sale of preferred stock, net of issuance costs	$ 20,000,000
Convertible Note One
Debt Obligations [Line Items]
Convertible note draws		4,500,000
Convertible Note Two
Debt Obligations [Line Items]
Convertible note draws		$ 0

Debt Obligations - Principal Re

Debt Obligations - Principal Repayments Due Under Term Loan (Details) - Term Loan	Sep. 30, 2016USD ($)
Debt Instrument [Line Items]
2,016	$ 1,513,915
2,017	6,389,782
2,018	5,163,822
Total Growth Term Loan payments	13,067,519
Less discount and deferred financing costs	(329,708)
Plus final fee premium	419,256
Total Growth Term Loan, net	$ 13,157,067

Other Agreements - Additional I

Other Agreements - Additional Information (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock				5,587
Asset purchase agreement fixed payments paid for first two years	$ 740,000			$ 740,000
Percentage on annual revenues for cash consideration to be paid				6.00%
Asset purchase agreement aggregate cash compensation paid	$ 15,000,000			$ 15,000,000
Deferred payment obligation interest percentage	5.00%			5.00%
Discount rate used to calculate asset purchase obligation				2.50%
Debt instrument, amortization expense				$ 156,103	$ 229,232
Research and development	$ 1,910,116		$ 1,309,573	$ 6,515,808	2,951,009
Agreement expiration date				Oct. 31, 2019
Description on termination of agreement				The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy
Service Revenue	407,836		37,000	$ 1,991,567	150,292
Recognition of deferred revenue				160,106
Collaborative Arrangement
Other Agreements [Line Items]
Service Revenue	128,630			$ 158,192
LTC
Other Agreements [Line Items]
Agreement commencement period				2016-03
Non-cancellable purchase order value						$ 250,000
Agreement expiration date				2021-03
Automatic renewal term of agreement				2 years
Agreement termination notice period				60 days
Number of days material breach remains uncured				30 days
Bristol-Myers Squibb
Other Agreements [Line Items]
Agreement expiration date				May 11, 2019
Agreement termination notice period				90 days
Number of days material breach remains uncured				60 days
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	1,000,000			$ 1,000,000
Research and development		$ 100,000
Invetech PTY Ltd. Agreement
Other Agreements [Line Items]
Research and development	287,100		150,000	2,310,758	150,000
Growth Term Loan A
Other Agreements [Line Items]
Debt instrument, amortization expense	46,727		31,595	148,859	120,627
Minimum payments of pledged intangible assets due in 2014	868,750			868,750
Minimum payments of pledged intangible assets due in 2015	868,750			868,750
Minimum payments of pledged intangible assets due in first quarter of 2016	868,750			868,750
Minimum payments of pledged intangible assets due in second quarter of 2016	362,500			362,500
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due in current year	543,750			543,750
Asset purchase agreement quarterly installments due in 2017	800,000			800,000
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	127,518	$ 283,621		127,518
Debt instrument, amortization expense	51,636		$ 51,481	156,103	$ 229,232
Minimum | NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2018	$ 400,000			$ 400,000

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Payments Due (Details) - NuvoGen Asset Purchase Agreement	Sep. 30, 2016USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2,016	$ 181,250
2,017	800,000
2,018	400,000
2,019	400,000
2,020	400,000
2021 and beyond	6,698,743
Total NuvoGen obligation payments	8,879,993
Less discount	(127,518)
Total NuvoGen obligation, net	$ 8,752,475

Net Loss per Share - Reconcilia

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net loss	$ (6,488,442)	$ (5,157,663)	$ (20,366,469)	$ (15,698,139)
Accretion of stock issuance costs				(35,046)
Accretion of Series E warrant discount				(127,616)
Series E and D, Convertible Preferred Stock dividends				(1,165,932)
Net loss attributable to common stockholders	$ (6,488,442)	$ (5,157,663)	$ (20,366,469)	$ (17,026,733)
Denominator:
Weighted-average common shares outstanding-basic and diluted	7,053,010	6,829,687	6,985,924	3,735,852
Net loss per share attributable to common stockholders, basic and diluted	$ (0.92)	$ (0.76)	$ (2.92)	$ (4.56)
Series E Warrants
Numerator:
Accretion of Series E warrant discount	$ 0	$ 0	$ 0	$ (127,616)

Net Loss per Share - Outstandin

Net Loss per Share - Outstanding Options and Warrants Excluded from Computation of Diluted Net Loss per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	1,200,644	590,139
Restricted Stock Units R S U
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	350,499	27,500
Warrant | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	219,723	170,587

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	May 11, 2015	Jan. 15, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Dec. 31, 2015	Aug. 22, 2014
Class Of Warrant Or Right [Line Items]
Proceeds from exercise of warrants						$ 8,948
Loss on change in fair value of the preferred stock and convertible note warrants			$ 0	$ 0	$ 0	$ 239,683
Fair value of the preferred stock warrant liability			$ 0		$ 0			$ 0
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	23,396						5,317		2,512,562
Warrants exercise price	$ 23.51		$ 23.51		$ 23.51		$ 23.51		$ 0.2189
Warrant Expiration Date					Aug. 22, 2024
Series C-1 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Preferred stock warrants forfeited and cancelled	1,290,350
Series C-2 Redeemable Convertible Preferred Stock | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	1,488
Warrants exercise price	$ 24.23
Series D Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Conversion of stock, shares issued	6,729
Proceeds from exercise of warrants	$ 1,752
Common Stock Warrants one
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares							45,307
Warrants exercise price			2.76		$ 2.76		$ 2.759
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares		9,311,586
Warrants exercise price		$ 0.2189	$ 14		$ 14
Warrant Expiration Date					Jan. 15, 2022
Aggregate consideration		$ 1,354
Convertible Note Warrants | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	144,772
Warrants exercise price	$ 14

Warrants -Summary of Outstandin

Warrants -Summary of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	May 11, 2015	Jan. 15, 2015	Aug. 22, 2014
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	144,772
Exercise Price/Share	$ 14				$ 0.2189
Expiration Date	2,022
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	931
Exercise Price/Share	$ 6.45
Expiration Date	2,019
Common Stock Warrants one
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	45,307
Exercise Price/Share	$ 2.76	$ 2.759
Expiration Date	2,026
IPO | Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants			144,772
Exercise Price/Share				$ 14
IPO | Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants			931
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	28,713
Exercise Price/Share	$ 23.51	$ 23.51		$ 23.51		$ 0.2189
Expiration Date	2,024
Series E Redeemable Convertible Preferred Stock | IPO
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants			23,396

Redeemable Convertible Prefer59

Redeemable Convertible Preferred Stock - Additional Information (Details)	May 11, 2015$ / sharesshares	Mar. 31, 2014USD ($)$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Mar. 31, 2016$ / shares	Dec. 31, 2015shares	Aug. 22, 2014$ / shares
Class Of Stock [Line Items]
Common stock, shares authorized	600,000,000		600,000,000	200,000,000		200,000,000			200,000,000
Preferred stock, shares authorized			472,083,383
Reverse stock split						one-for-107.39
Accretion of Series E warrant discount | $							$ 127,616
Preferred Stock
Class Of Stock [Line Items]
Fair value of warrants | $				$ 5,665,000		$ 5,665,000
Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share | $ / shares		$ 0.2189	$ 0.2189	$ 0.2189		$ 0.2189
Issuance of preferred stock, net of issuance cost, shares		354,062	34,099,476
Warrants exercise price | $ / shares	$ 23.51			23.51		23.51		$ 23.51		$ 0.2189
Common stock, conversion basis	0.009	1
Preferred Stock Par Or Stated Value Per Share | $ / shares				0.001		$ 0.001
Liquidation preference						The Series D Stock and Series E Stock liquidation preference was equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared.
Outstanding convertible preferred stock	428,237
Preferred stock cumulative dividend percentage						8.00%
Series E Redeemable Convertible Preferred Stock | Maximum
Class Of Stock [Line Items]
Convertible preferred stock, shares authorized			99,132,024
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Common stock, conversion basis	0.030
Preferred Stock Par Or Stated Value Per Share | $ / shares				0.001		$ 0.001
Stock holders voting percentage required for stock redemption						66.67%
Outstanding convertible preferred stock	38,973
Series B Preferred Stock
Class Of Stock [Line Items]
Common stock, conversion basis	0.011
Preferred Stock Par Or Stated Value Per Share | $ / shares				0.001		$ 0.001
Outstanding convertible preferred stock	75,835
Series C Preferred Stock
Class Of Stock [Line Items]
Preferred Stock Par Or Stated Value Per Share | $ / shares				0.001		0.001
Series D Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share | $ / shares				0.2189		0.2189
Common stock, conversion basis	0.009
Preferred Stock Par Or Stated Value Per Share | $ / shares				$ 0.001		$ 0.001
Liquidation preference						The Series D Stock and Series E Stock liquidation preference was equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared.
Outstanding convertible preferred stock	1,305,984
Preferred stock cumulative dividend percentage						8.00%
A B C D Stock And Series E Stock
Class Of Stock [Line Items]
Stock holders voting percentage required for stock redemption						60.00%
Series C-1
Class Of Stock [Line Items]
Common stock, conversion basis	0.014
Outstanding convertible preferred stock	191,406
Series C-2
Class Of Stock [Line Items]
Common stock, conversion basis	0.009
Outstanding convertible preferred stock	93,757
Preferred Shares Excluding Dividends
Class Of Stock [Line Items]
Outstanding convertible preferred stock	2,134,192
Series D And E Preferred Stock Cumulative Dividends
Class Of Stock [Line Items]
Outstanding convertible preferred stock	374,632
Series E Warrants
Class Of Stock [Line Items]
Purchase of warrant exercise price per share | $ / shares			$ 0.001
Purchase price of preferred stock per Series E warrant | $ / shares		$ 0.0001	0.0001
Warrants exercise price | $ / shares		$ 0.001	$ 0.001
Financial institution warrant issued, share		118,017	11,366,486
Proceeds from Issuance of preferred stock and warrants | $		$ 77,634	$ 7,476,879
Fair value of warrants | $				$ 1,890,000		$ 1,890,000
Accretion of Series E warrant discount | $				$ 0	$ 0	0	$ 127,616
Warrant Issuance Costs | $						$ 48,384
Preferred stock accreted redemption period						5 years
Series E Warrants | Maximum
Class Of Stock [Line Items]
Financial institution warrant issued, share			33,044,008
Series E Warrants | Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share | $ / shares				$ 0.1645		$ 0.1645
Tranche One | Series E Redeemable Convertible Preferred Stock | Maximum
Class Of Stock [Line Items]
Financial institution warrant issued, share			49,566,012
Tranche One | Series E Warrants | Maximum
Class Of Stock [Line Items]
Financial institution warrant issued, share			16,522,004

Redeemable Convertible Prefer60

Redeemable Convertible Preferred Stock - Summary of Preferred Stock (Details)	May 11, 2015USD ($)shares
Class Of Stock [Line Items]
Carrying value including cumulative dividends | $	$ 57,356,049
Preferred shares before IPO including cumulative dividends	217,515,139
Common shares after IPO including dividends	2,508,824
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering | $	$ 1,403,007
Preferred Shares Before IPO	1,292,084
Common Shares After IPO	38,973
Series B Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering | $	$ 2,100,149
Preferred Shares Before IPO	6,789,712
Common Shares After IPO	75,835
Series C-1
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering | $	$ 4,569,063
Preferred Shares Before IPO	13,242,612
Common Shares After IPO	191,406
Series C-2
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering | $	$ 2,225,619
Preferred Shares Before IPO	9,948,331
Common Shares After IPO	93,757
Series D Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering | $	$ 30,370,273
Preferred Shares Before IPO	140,252,678
Common Shares After IPO	1,305,984
Series E Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering | $	$ 7,879,873
Preferred Shares Before IPO	45,989,722
Common Shares After IPO	428,237
Preferred Shares Excluding Dividends
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering | $	$ 48,547,984
Preferred Shares Before IPO	217,515,139
Common Shares After IPO	2,134,192
Series D And E Preferred Stock Cumulative Dividends
Class Of Stock [Line Items]
Common Shares After IPO	374,632
Cumulative Dividends | $	$ 8,808,065

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jan. 01, 2016	Dec. 31, 2015	May 11, 2015	Feb. 04, 2014
Class Of Stock [Line Items]
Amendment date of entity incorporation				May 11, 2015
Common stock, shares authorized		200,000,000		200,000,000			200,000,000	600,000,000	600,000,000
Common stock, par value		$ 0.001		$ 0.001			$ 0.001
Common stock, shares issued		7,060,269		7,060,269			6,845,638
Common stock, shares outstanding		7,058,873		7,058,873			6,844,242
Preferred stock, shares authorized		10,000,000		10,000,000
Preferred stock, par value		$ 0.001		$ 0.001
Preferred stock, issued		0		0
Stock-based compensation expense		$ 229,918	$ 77,239	$ 552,054	$ 223,787
2014 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Maximum aggregate number of common stock available purchase under employee stock purchase plan		110,820		110,820
Shares reserved for issuance						68,442
Maximum contribution eligible compensation during a period to purchase common stock		15.00%		15.00%
Common stock issuance offering date				Jan. 1, 2016
Fair market value of company common stock, shares offering price				85.00%
Fair market value of company common stock, shares purchase price				85.00%
Common stock shares issued				39,978
Weighted average price per share		$ 2.54		$ 2.54
Restricted Stock Units R S U
Class Of Stock [Line Items]
Unrecognized compensation expense		$ 730,655		$ 730,655
Compensation expense period expected to be recognized				1 year
Number of shares unvested and outstanding		350,499		350,499			27,500
Two Thousand Fourteen Equity Incentive Plan
Class Of Stock [Line Items]
Number of shares available for issuance		68,450		68,450
Options to purchase common stock outstanding		1,200,644		1,200,644
Options fully vested				571,800
Accelerated vesting of unvested stock options	8,957
Options exercise period	2 years
Incremental stock-based compensation expense		$ 0		$ 13,500
Two Thousand Fourteen Equity Incentive Plan | Employee Stock Option
Class Of Stock [Line Items]
Options to purchase common stock outstanding		1,200,644		1,200,644			736,645
Unrecognized compensation expense		$ 1,064,203		$ 1,064,203
Compensation expense period expected to be recognized				2 years 4 months 28 days

Stockholders Equity - Summary o

Stockholders Equity - Summary of Stock Option Plans Activity (Details) - Two Thousand Fourteen Equity Incentive Plan - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Ending Balance	1,200,644
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	736,645
Number of Shares, Granted	548,400
Number of Shares, Exercised	(4,712)
Number of Shares, Forfeited	(79,689)
Number of Shares, Ending Balance	1,200,644	736,645
Number of Shares, Vested and expected to vest	1,111,699
Number of Shares, Exercisable	571,800
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 4.18
Weighted-Average Exercise Price Per Share, Granted	2.47
Weighted-Average Exercise Price Per Share, Exercised	2.15
Weighted-Average Exercise Price Per Share, Forfeited	4.90
Weighted-Average Exercise Price Per Share, Ending Balance	3.36	$ 4.18
Weighted-Average Exercise Price Per Share, Vested and expected to vest	3.37
Weighted-Average Exercise Price Per Share, Exercisable	$ 3.44
Weighted-Average Remaining Contractual Life, Outstanding	7 years 10 months 24 days	7 years 6 months
Weighted-Average Remaining Contractual Life, Vested and expected to vest	7 years 9 months 18 days
Weighted-Average Remaining Contractual Life, Exercisable	6 years 6 months
Aggregate Intrinsic Value, Balance	$ 48,246	$ 947,794
Aggregate Intrinsic Value, Vested and expected to vest	48,086
Aggregate Intrinsic Value, Exercisable	$ 40,266

Stockholders Equity - Summary63

Stockholders Equity - Summary of RSU Plans Activity (Details) - Restricted Stock Units R S U	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Restricted Stock Units (RSU)
Balance at December 31, 2015 | shares	27,500
Granted | shares	379,761
Vested | shares	(36,762)
Forfeited | shares	(20,000)
Balance at September 30, 2016 | shares	350,499
Vested and expected to vest at September 30, 2016 | shares	333,117
Weighted Average Grant Date Fair Value Per Share
Balance at December 31, 2015 | $ / shares	$ 5.45
Granted | $ / shares	2.44
Vested | $ / shares	2.90
Forfeited | $ / shares	2.46
Balance at September 30, 2016 | $ / shares	2.43
Vested and expected to vest at September 30, 2016 | $ / shares	$ 2.43

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended	9 Months Ended
	Jun. 30, 2012	Sep. 30, 2016	Feb. 29, 2016	Dec. 31, 2015
Commitments And Contingencies [Line Items]
Lease expiration term		The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona.
Lease extension term, in years		5 years
Expected increase in lease rent		$ 804,000
Incentive from landlord		710,000
Leasehold improvements		1,847,378	$ 710,000	$ 224,061
Monthly accreted lease term as reduction of rent expense		11,833
Capital lease commitments		148,900
Lease equipment financing arrangement		$ 36,000
Lease expiration date of lease payments not in schedule		2017-12
Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, milestone accrued or paid	$ 0
Minimum
Commitments And Contingencies [Line Items]
Capital lease commitments of computer equipment period		36 months
Minimum | Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, contingent milestone payments	$ 50,000
Non-exclusive license agreement, future royalties	3.00%
Maximum
Commitments And Contingencies [Line Items]
Capital lease commitments of computer equipment period		48 months
Maximum | Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, contingent milestone payments	$ 1,000,000
Non-exclusive license agreement, future royalties	6.00%

Commitments and Contingencies65

Commitments and Contingencies - Minimum Real Estate Lease Payments Before Common Area Maintenance Charges (Details)	Sep. 30, 2016USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,016	$ 126,987
2,017	510,125
2,018	512,533
2,019	514,977
2,020	517,457
2021 and beyond	43,139
Total minimum lease payments	$ 2,225,218

Commitments and Contingencies66

Commitments and Contingencies - Schedule Of Product Warranty Liability (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 20,213
Cost of warranty claims	(67,663)	$ (545)
Warranty accrual	83,745	17,225
Ending balance	$ 36,295	$ 16,680

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income tax examination, likelihood of unfavorable settlement			greater than 50 percent
Uncertain tax positions	$ 0		$ 0		$ 0
Accrued interest or penalties	0		0		$ 0
Recognized interest or penalties	$ 0	$ 0	$ 0	$ 0